Director, President and CEO, 10% Owner · ADARx Pharmaceuticals, Inc. · ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)
Side
A
Value
—
Shares
1.02M
Price
—
Executed
Sep 24, 2026
Disclosed
Sep 28, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 24 executedSep 28, 2026 disclosed
ADRX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)
Ticker
ADRX
Shares
1.02M
Price per share
$0
Execution date (reported)
Sep 24, 2026
Owned after transaction
1.02M shares
Days from execution to publication
4
What this establishes
Li Zhen filed this Form 4 reporting a grant or award of ADRX on Sep 24, 2026. It became public on Sep 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, President and CEO, 10% Owner
Li Zhencik:0001729510
Issuer
ADARx Pharmaceuticals, Inc.cik:0001802369
Revision history · 0
No field has changed since this record was first ingested.
